Gary Steinecker
Medical Oncology · Oak Lawn, ILNPI 1699880872
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,150 of the $10,007 with a category attached, or 61.5%. 27 manufacturers reported payments, led by Pfizer at 49.5% of the total. Reporting peaked in 2020 at $5,190 and has fallen 99.6% since, to $23 in 2025.
Across 67 payments — averaging $149.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$5K
- AstraZeneca$2K
- G1 Therapeutics, Inc.$2K
- Merck$215
- Novartis$189
- Athenex Pharmaceutical Division, LLC$150
- plus $665 from 21 others
What the payments were for
- Consulting fees$6,15061%
- Speaking & faculty fees$1,65016%
- Travel & lodging$8969%
- Food & beverage$1,27713%
- Education$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 8 | $4,952 |
| AstraZeneca | 4 | $2,336 |
| G1 Therapeutics, Inc. | 1 | $1,500 |
| Merck | 10 | $215 |
| Novartis | 10 | $189 |
| Athenex Pharmaceutical Division, LLC | 1 | $150 |
| Comsort, Inc | 1 | $100 |
| Amgen | 3 | $65 |
| Lilly USA, LLC | 3 | $54 |
| Eisai Inc. | 3 | $48 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $39 |
| Johnson & Johnson(2 entities) | 2 | $37 |
| EMD Serono, Inc. | 1 | $34 |
| Genentech USA, Inc. | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Sanofi | 2 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Rigel Pharmaceuticals, Inc. | 1 | $25 |
| Beigene USA, Inc. | 1 | $22 |
| Novo Nordisk | 1 | $18 |
| AbbVie | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
| Bristol Myers Squibb | 1 | $15 |
| Seagen Inc. | 1 | $14 |
| Sun Pharmaceutical Industries Inc. | 1 | $13 |
| Incyte Corporation | 1 | $13 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COSELA$1,500
- IBRANCE$1,167
- Oral Paclitaxel$150
- Encequidar$150
- KEYTRUDA$100
How this compares
$10,007 in reported general payments places this provider in the 75th percentile of 144 medical oncology providers in Illinois.
Other medical oncology in Oak Lawn
- Prashant JoshiOak Lawn$5K
- Nada ShermanOak Lawn$5K
- Ruta RaoChicago$328K
- Sunandana ChandraChicago$292K
- William GradisharChicago$289K
- Timothy KuzelOrland Park$265K
- Devalingam MahalingamChicago$252K
- Mary FidlerChicago$241K
- James WallaceChicago$229K
- Andrzej JakubowiakChicago$215K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.